MedTrace Logo

DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma

NCT03905902 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2021-12-23

No results posted yet for this study

Summary

Multi-center, phase III trial of DCVAC/OvCa added to standard of care treatments for relapsed ovarian cancer. Patients will receive study treatment until all doses are administered, or other criteria are met.

Conditions

Interventions

BIOLOGICAL

DCVAC/OvCa

activated autologous dendritic cells

BIOLOGICAL

DCVAC/OvCa placebo

placebo for activated autologous cells

Sponsors & Collaborators

  • European Network of Gynaecological Oncological Trial Groups (ENGOT)

    collaborator OTHER

  • SOTIO a.s.

    lead INDUSTRY

Principal Investigators

  • Harald Fricke, MD PhD · SOTIO a.s.

  • David Cibula, Prof. MD PhD · The Central and Eastern European Gynecologic Oncology Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-31
Primary Completion
2021-08-31
Completion
2021-08-16

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03905902 on ClinicalTrials.gov